. Author manuscript; available in PMC: 2021 Jul 1.

Published in final edited form as: J Pain. 2019 Nov 21;21(7-8):798–807. doi: 10.1016/j.jpain.2019.11.007

Table 2.

Results of Simultaneous Multiple Regression Analyses Predicting 6 Month Follow-up

	β/B (SE)
Predictor	Intent-to-Treat (n = 35)	Per Protocol (n = 28)
Current opioid misuse
Baseline	.76^**/.76 (.10)^**	.77^**/.76 (.11)^**
MED	.13/.01 (.01)	.14/.01 (.01)
Pain duration	.03/.002 (.01)	.03/.002 (.01)
Group	.36^*/5.39 (1.71)^*	.36^**/5.39 (1.56)^**
Model R²	.76 (.08)^****	.75 (.12)^****
Pain interference
Baseline	.55^**/.75 (.27)^*	.59^*/.75 (.27)^*
MED	.15/.02 (.02)	.16/.02 (.02)
Pain duration	.16/.01 (.01)	.17/.01 (.01)
Group	.41^*/6.50 (2.02)^	.40^*/6.5 (2.5)^
Model R²	.54 (.13)^****	.56 (.15)^****
Pain behavior
Baseline	.36^/.39 (.14)^*	.34^/.39 (.14)^**
MED	.51^**/.03 (.01)^*	.57^**/.03 (.11)^*
Pain duration	−.10/−.01 (.01)	−.10/−.01 (.01)
Group	.41^**/4.19 (2.07)^	.42^**/4.19 (2.07)^
Model R²	.37 (.15)^*	.36 (.13)^*
Pain intensity
Baseline	.30/.36 (.21)	.31/.36 (.21)
MED	.09/.002 (.01)	.10/.002 (.01)
Pain duration	.13/.002 (.003)	.14/.002 (.003)
Group	.53^**/1.94 (.68)^*	.54^**/1.94 (.68)^*
Model R²	.40 (.13)^****	.39 (.13)^***
Prescribed opioid dose
Baseline	.95^**/.94 (.06)^**	.96^**/.94 (.06)^**
Pain duration	.05/.04 (.04)	.05/.04 (.04)
Group	−.04/−6.24 (5.76)	−.04/− 6.24 (5.76)
Model R²	.95 (.02)^***	.96 (.02)^***

P ≤ .05,

^**

P ≤ .01,

^***

P ≤ .005,

^****

P ≤ .001.

Measures: Current opioid misuse: Current opioid misuse measure, Pain interference: PROMIS pain interference short form 8a; Pain behavior: PROMIS pain behavior v1.1 short form 7a; Pain intensity: 0 to 10 numerical rating scale of average pain for past week; Prescribed opioid dose: Morphine equivalent dose for all prescribed opioids.

Group (0 = integrated intervention, 1 = usual care).